Adult Pilot Study for Reference Ranges and Optimal Cut-offs for the Sucrose Challenge Test and Sucrose Breath Test

Congenital Sucrase-Isomaltase Deficiency Clinical Trial

Official title:

Adult Pilot Study to Establish the Reference Ranges and Optimal Cut-offs for Oral 50g Sucrose Challenge Test & 13C-Sucrose Breath Test for CSID Cases (Previously Diagnosed Sucraid Responders) & Controls (GI Asymptomatic Healthy Volunteers)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05045495
• Other study ID #: SSDXA-12
• Status: Completed
• Start date: August 30, 2021
• Est. completion date: February 28, 2022

Study information

• Verified date: May 2022
• Source: QOL Medical, LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

An adult pilot study to establish the normal reference range and optimal cutoffs for the oral 50g Sucrose Challenge Test (SCT) and the 50g 13C-Sucrose Breath Test (CBT) for patients with CSID and healthy controls. This study will enroll 120 healthy controls and 50 CSID patients. No study drug will be administered during this study.

Description:

In an effort to mimic the real-world diagnostic setting for these tests, this study will be conducted virtually using a central site with telemedicine capabilities and electronic data capture software to collect data in real time via a mobile app. Subject will complete 3 visits within 21 days. Eligible subjects will undergo the following tests:

1. 50g 13C-Sucrose Breath Test (CBT)

2. Sucrose Intolerance Hydrogen Methane Breath Test (HBT)

3. Sucrose Challenge Test (SCT)

4. Buccal swab for CSID Genetic Testing (GT)

The primary aim is to establish the reference/normal ranges and optimal cutoff values for the SCT and CBT.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 211
• Est. completion date: February 28, 2022
• Est. primary completion date: February 28, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subject must provide informed consent prior to any study procedures being performed.

• Subject is a U.S. resident, and speaks and understands English

• Subject is male or female, = 18 years old.

• CSID Cases must have been on Sucraid for at the last 12 months.

• Healthy Volunteers do not have a CSID diagnosis or other chronic gastrointestinal conditions.

• Subject must have their own Android or Apple device to access the mobile patient app.

Exclusion Criteria:

• Females who are lactating or pregnant.

• Subjects with allergy to sucrose.

• Subjects with causes of abdominal pain or altered bowel habits other than symptoms -related to CSID (in CSID group) such as SIBO, IBD, celiac disease, pancreatitis, or -gastrointestinal bleeding.

• Diabetes mellitus.

• Use of systemic antibiotics, had a barium study, colonoscopy, unexplained runny diarrhea, or similar within 14 days prior to informed consent. Potential subjects can be re-screened once they meet this criterion.

• Recent febrile illness.

• Subject has major physical or psychiatric illness within the last 6 months that in the opinion of the investigator would affect the subject's ability to complete the trial.

Related Conditions & MeSH terms

• Congenital Sucrase-Isomaltase Deficiency

Intervention

Diagnostic Test:
• Sucrose Hydrogen Methane Breath Test
Subjects will collect 2 buccal swabs for the sucrase genetic test and then subjects will simultaneously conduct the sucrose challenge test, sucrose hydrogen methane breath test, and the 13C-sucrose following ingestion of 50-grams of sucrose (table sugar) mixed with 8 ounce of water.

Locations

Country	Name	City	State
United States	Science 37-Recruiting Nationally	Culver City	California

Sponsors (1)

Lead Sponsor	Collaborator
QOL Medical, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Establish the normal reference range for the 50g Sucrose Challenge Test (SCT)	Reference ranges will be estimated by the lower 2.5th percentile and upper 97.5th percentile of the distribution of test results for the case and control populations.	4 hours post ingestion of sucrose
Primary	Establish the optimal cutoff values for the 50g Sucrose Challenge Test (SCT)	The mean and peak symptom severity score following sucrose ingestion will serve as markers of sucrase activity. The cutoff for the SCT will be determined by the maximum Youden Index that differentiates cases and controls.	4 hours post ingestion of sucrose
Primary	Establish the normal reference range for the 50g 13C-Sucrose Breath Test (CBT)	Reference ranges will be estimated by the lower 2.5th percentile and upper 97.5th percentile of the distribution of test results for the case and control populations.	4 hours post ingestion of sucrose
Primary	Establish the optimal cutoff values for the 50g 13C-Sucrose Breath Test (CBT)	The mean and peak symptom severity score following sucrose ingestion will serve as markers of sucrase activity. The cutoff for the SCT will be determined by the maximum Youden Index that differentiates cases and controls.	4 hours post ingestion of sucrose
Secondary	Compare the positive predictive values (PPV) of the Sucrose Challenge Test (SCT) with the PPV of the Sucrose Hydrogen Methane Breath Test (HBT)	PPV of SCT relative to the HBT and percentage of Sucraid® Responders in CSID cases and asymptomatic controls, and in cases confirmed by each of the following three diagnostic tools: HBT, CBT, and SCT.	4 hours post ingestion of sucrose
Secondary	Compare the negative predictive values (NPV) of the Sucrose Challenge Test (SCT) with the NPV of the Sucrose Hydrogen Methane Breath Test (HBT)	NPV of SCT relative to the HBT and percentage of Sucraid® Responders in CSID cases and asymptomatic controls, and in cases confirmed by each of the following three diagnostic tools: HBT, CBT, and SCT.	4 hours post ingestion of sucrose
Secondary	Compare the positive predictive values (PPV) of the 13C-Sucrose Breath Test (CBT) with the positive predictive value of the Sucrose Hydrogen Methane Breath Test (HBT)	PPV of the CBT relative to the HBT and percentage of Sucraid® Responders in CSID cases and asymptomatic controls, and in cases confirmed by each of the following three diagnostic tools: HBT, CBT, and SCT.	4 hours post ingestion of sucrose
Secondary	Compare the negative predictive value (NPV) of the 13C-Sucrose Breath Test (CBT) with the NPV of the Sucrose Hydrogen Methane Breath Test (HBT)	NPV of the CBT relative to the HBT and percentage of Sucraid® Responders in CSID cases and asymptomatic controls, and in cases confirmed by each of the following three diagnostic tools: HBT, CBT, and SCT.	4 hours post ingestion of sucrose